Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data For Trodusquemine (MSI-1436) At American Diabetes Association

Genaera Corporation (Nasdaq: GENR) announced a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera’s lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.

More: continued here

Filed under: Clinical Trials on June 10th, 2008